AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01957436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
Study NCT01957436 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
Study NCT01957436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Deprivation Therapy
Description: The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
Study NCT03404310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Participant will take one 220mg tablet twice daily for three months.
Study NCT03404310 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Gelatin Tablet)
Description: Participant will take one tablet twice daily for three months.
Study NCT03834103 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-rehabilitation program and protein supplement
Description: Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up.
Study NCT00877279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CosmoDerm1
Description: CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
Study NCT00877279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Soft
Description: Dermal Filler
Study NCT02003352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Neurological Rehabilitation
Description: Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
Study NCT01027442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosa-supported single-type guides
Description: Compute generated Mucosa-supported single-type guides
Study NCT01027442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone-supported guides
Description: Computer generated, Multiple type Bone-supported guides
Study NCT01027442 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental Implants
Description: Dental implants placed via conventional free-hand method
Study NCT04883736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Gel Microsphere, 0.1%
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT04883736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT04883736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT00907309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMET
Description: Participants will receive the iMET intervention
Study NCT00907309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMET/TE
Description: Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
Study NCT04501471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAAF-T
Description: Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
Study NCT04501471 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fuel for Families
Description: Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
Study NCT01104519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Description: Oral doses of 2000 mg of Niaspan once daily for 7 days.
Study NCT01104519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Oral doses of placebo once daily for 7 days.
Study NCT03811041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDA
Description: Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
Study NCT03811041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Cares
Description: Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
Study NCT03811041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental depression
Description: Parents of depressed adolescents will be met for a screening test of depression.
Study NCT00053989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: iv
Study NCT00053989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft-versus-tumor induction therapy
Description: iv
Study NCT00053989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: iv
Study NCT00053989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: iv
Study NCT00053989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: injection
Study NCT00053989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: iv
Study NCT00053989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: oral
Study NCT00053989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral
Study NCT00053989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT00053989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: iv
Study NCT00053989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: iv
Study NCT00053989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: iv
Study NCT00166296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
Study NCT00166296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
Study NCT01250990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
Study NCT01250990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03309839 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
Study NCT03721640 — intervention group
Intervention type: OTHER
Intervention: electrocardiogram
Description: Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
Study NCT01525316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
Study NCT01525316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
Study NCT04433234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5141b
Description: Administered via subcutaneous injection once weekly
Study NCT05349825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis and Losartan plazma level measurement
Description: 20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry
Study NCT03509740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Description: 100 mg tramadol in 100 ml saline with slow infusion
Study NCT03509740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
Study NCT02007642 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling / Body fluid sampling
Description: During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite...
Study NCT00502255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Buddy system
Description: Patients are followed on distance by the Health Buddy system.
Study NCT00502255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring in patients with heart failure
Description: Health Buddy in patients home situation.
Study NCT00948779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: antibiotic education for children in an emergency care unit
Description: Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
Study NCT00948779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antibiotic education for children in an emergency care unit
Description: Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
Study NCT03077490 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal mesh Uphold TM Vaginal Support System
Study NCT03077490 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal mesh Uphold TM Vaginal Support System.
Study NCT04220177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SETA LATECBA Stent Grafts
Description: ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
Study NCT02865720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CINRYZE 500 U
Description: IV infusion administered twice weekly
Study NCT02865720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CINRYZE 1000 U
Description: IV infusion administered twice weekly
Study NCT03006770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: Local intramuscular (IM) injections of PLX-PAD in the index leg.
Study NCT03006770 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local intramuscular (IM) injections of Placebo in the index leg.
Study NCT04864574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden installation
Description: Garden installation: 6 raised planting beds (4x6x16) configured in a single line with direct sun at least 6 hrs./day, close to hose bib, sufficient distances to allow working from most sides, vegetable vines spill over space, and storage unit for tools.~Planting beds constructed from a standard kit. Beds filled with high quality growing medium.~Plants selection criteria: a) documented harvest success in NC Piedmont; b) able to be eaten raw, c) harvest times at the same time (except strawberries).~Designated beds and plants: Bed 1: 4 pepper, 2 tomato; Bed 2: 20 bean on 2 mini-teepees, 2 cucumber (trellised); Bed 3: 1 yellow squash, 1 zucchini; Bed 4: 2 blueberry bushes, 12 strawberry; Bed 5: 2 cantaloupe. Bed 6: 2 watermelon. 2 Blackberries planted at ground level on trellis.
Study NCT04540705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04540705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Specified dose on specified days
Study NCT04540705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days
Study NCT00630565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
Study NCT02561494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Study NCT02561494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03023592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25 mg orally twice a day for 24 weeks
Study NCT05000567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week nordic hamstring exercise program
Description: 12 weeks progressive eccentric strength training program targetting the hamstring muscles.
Study NCT00520858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise (RE)
Study NCT00630565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
Study NCT00630565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
Study NCT00520858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise (AE)
Study NCT00520858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance and Aerobic Exercise (RAE)
Study NCT02030782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) for depression
Description: Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
Study NCT02030782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care enhanced by provider education regarding depression evaluation and management
Study NCT03661138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered orally.
Study NCT03661138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Placebo is administered orally.
Study NCT03661138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroids (TCS)
Description: It is administered concomitantly with upadacitinib or placebo.
Study NCT02038894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intubated with Sevoflurane (IS)
Description: Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
Study NCT02038894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intubated with Propofol (IP)
Description: Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
Study NCT02038894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran - no intubation
Description: A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
Study NCT02038894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT00386022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
Study NCT00386022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL-GLU GnRH antagonist
Description: A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
Study NCT00386022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Description: transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
Study NCT03457519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Children's Automated Respiration Monitor (ChARM)
Description: The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
Study NCT03381755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half-dose ticagrelor
Description: To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
Study NCT03381755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose ticagrelor
Description: To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
Study NCT00387673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatosensory Stimulation and Massed Practice Training
Description: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.